Who
Bradley Saenger
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Tonix Pharmaceuticals Holding.
In numbers
- Trades disclosed
- 41
- Buys
- 2
- Sells
- 0
- Bought
- $5,230
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 27 May 2016
- Last trade
- 30 Jun 2026
- Last filed
- 9 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 9 Jul 2026 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code J | $16K1,453 at $10.91 | filing |
| 30 Jun 2026filed 9 Jul 2026 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code J | $16K1,453 at $10.91 | filing |
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,012 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,011 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,012 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,011 at $0.00 | filing |
| 31 Dec 2025filed 17 Feb 2026 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code A | $9,407701 at $13.42 | filing |
| 25 Feb 2025filed 27 Feb 2025 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,792 at $0.00 | filing |
| 25 Feb 2025filed 27 Feb 2025 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,792 at $0.00 | filing |
| 5 Feb 2025filed 27 Feb 2025 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code J | —0.04 at $0.00 | filing |
| 27 Feb 2024filed 29 Feb 2024 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —282,000 at $0.00 | filing |
| 27 Feb 2024filed 29 Feb 2024 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —282,000 at $0.00 | filing |
| 23 Feb 2023filed 24 Feb 2023 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 23 Feb 2023filed 24 Feb 2023 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 15 Feb 2022filed 17 Feb 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,000 at $0.00 | filing |
| 15 Feb 2022filed 17 Feb 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,000 at $0.00 | filing |
| 15 Feb 2022filed 17 Feb 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,000 at $0.00 | filing |
| 15 Feb 2022filed 17 Feb 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,000 at $0.00 | filing |
| 30 Jun 2021filed 11 Feb 2022 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code A | $11K18,248 at $0.58 | filing |
| 23 Feb 2021filed 25 Feb 2021 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —540,000 at $0.00 | filing |
News
Tonix Pharmaceuticals Sets 2027 Phase 1 Target For TNX-801 Vaccine CandidateTNXP · rttnews.com · 15 Oct 2026Tonix Pharmaceuticals Begins Building Lyme Disease Drug Facility in Hamilton, MontanaTNXP · matr.net · 12 Oct 2026
0 headlines in the last 90 days name Bradley Saenger; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.